Niemann-Pick Type C in Infants

✓ Medically reviewed | Published: | Evidence level: 1A
An NIH research team has reported groundwork for a new treatment approach to Niemann-Pick disease type C in infants, a rare inherited disorder that damages the brain and other organs. Two drugs were FDA-approved for the neurological symptoms in 2024, but treatment options for the youngest patients remain limited.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pediatric Health

Quick Facts

Disease Type
Rare lysosomal storage disorder
Typical Frequency
Roughly 1 in 100,000 births
Main Genes
NPC1 and NPC2
FDA-Approved Drugs
Two, approved 2024

What is Niemann-Pick disease type C?

Quick answer: It is a rare inherited disorder in which cholesterol and other lipids build up inside cells because of mutations in the NPC1 or NPC2 genes.

Niemann-Pick disease type C (NPC) is a progressive lysosomal storage disorder. Mutations in NPC1, responsible for the large majority of cases, or in NPC2 disrupt the transport of cholesterol and other lipids out of lysosomes, causing harmful accumulation in the liver, spleen and brain. The condition is generally estimated to affect roughly 1 in 100,000 live births, though figures vary by source and population.

Symptoms depend on age at onset. Infants can present with prolonged jaundice, an enlarged liver and spleen, and developmental problems, while older children and adults more often show clumsiness, difficulty with eye movements, speech and swallowing problems, seizures, cognitive decline and psychiatric symptoms. Infantile-onset disease can progress especially quickly, which is why earlier intervention is a major research goal.

What treatments exist, and why are infants a special challenge?

Quick answer: Two drugs, arimoclomol and levacetylleucine, were FDA-approved in 2024 for neurological symptoms, but evidence in the youngest infants is limited.

In September 2024 the US FDA approved two oral therapies for NPC neurological manifestations: arimoclomol (Miplyffa) and levacetylleucine (Aqneursa). Before then, care relied mainly on supportive measures and, in some countries, miglustat. Approvals for these drugs were based on studies in children and adults, with age and weight limits set in each label, so infants have often fallen outside the studied populations.

Infants pose distinct challenges. Their disease can involve early liver involvement and rapidly progressing neurological decline, their dosing and drug delivery needs differ, and trials in such a small population are difficult to run. Research such as that highlighted by the NIH is aimed at building the scientific and clinical foundation needed to test treatments in this age group. Details of the specific approach should be confirmed from the NIH announcement and associated publication, and any new therapy would still need to prove safety and benefit in formal trials.

What should families know about diagnosis and early care?

Quick answer: Early recognition and referral to a metabolic or neurology specialist can allow earlier access to supportive care and clinical trials.

Diagnosis typically involves clinical evaluation, biomarker testing and genetic analysis of NPC1 and NPC2. Because early signs such as prolonged neonatal jaundice have many more common causes, NPC can be overlooked, and delays in diagnosis are well described in rare disease care. Genetic testing for siblings of an affected child is an important part of family counseling, as the condition is inherited in an autosomal recessive pattern.

Care is multidisciplinary, including neurology, hepatology, nutrition, physical and speech therapy, and palliative support as needed. Families can seek information from NIH resources and rare disease organizations, and ask specialists about registries and clinical trials for which their child might be eligible.

Frequently Asked Questions

No cure exists. Treatments aim to slow neurological progression and manage symptoms, and several approaches are under study.

It is autosomal recessive, meaning a child must inherit a disease-causing variant from each parent. Parents are typically unaffected carriers.

Their labels specify age and weight criteria based on the studied populations, and evidence in the youngest infants is limited. Families should consult a specialist about eligibility.

References

  1. National Institutes of Health. NIH research team lays groundwork for new treatment of Niemann-Pick Type C in infants. November 2026.
  2. US Food and Drug Administration. FDA approves first treatments for Niemann-Pick disease, type C. September 2024.
  3. National Institute of Neurological Disorders and Stroke. Niemann-Pick Disease Information Page.